The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?

LY2605541--A Preferential Hepato-Specific Insulin Analogue

(2014) S. Madsbad   DIABETES

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

(2013) M. C. Moore et al.   DIABETES

Self-Mixed/Split Insulin Regimen: A Serious Omission in the ADA/EASD Position Statement

(2013) Mayer B. Davidson   DIABETES CARE

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people

(2013) K. Khunti et al.   DIABETES CARE

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

(2013) Stephen C.L. Gough et al.   DIABETES CARE

Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

(2013) David R. Owens et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Insulin degludec: a new insulin for today?

(2013) G. A. Hitman   DIABETIC MEDICINE

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

(2013) Gerd Koehler et al.   DIABETOLOGIA

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

(2013) Yukiko Onishi et al.   Journal of Diabetes Investigation

European Medicines Agency must take account of cardiovascular harm associated with degludec insulin

(2013) T. A. Schmidt et al.   BMJ-British Medical Journal

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

(2013) Bernard Zinman et al.   Lancet Diabetes & Endocrinology

Hyperglycemia Slows Embryonic Growth and Suppresses Cell Cycle via Cyclin D1 and p21

(2012) Devon E. Scott-Drechsel et al.   DIABETES

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials

(2012) K. Esposito et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

(2012) Leo Niskanen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Humalog (lispro) for type 2 diabetes

(2012) Katherine Esposito et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes

(2012) Katherine Esposito et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The Past 200 Years in Diabetes

(2012) Kenneth S. Polonsky   NEW ENGLAND JOURNAL OF MEDICINE

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

Clinical Inertia as a Clinical Safeguard

(2011) Dario Giugliano   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

(2011) Meryl Brod et al.   VALUE IN HEALTH

Treatment regimens with insulin analogues and haemoglobin A1c target of

(2010) Dario Giugliano et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

(2009) S. R. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

How hypoglycaemia can affect the life of a person with diabetes

(2007) Brian M. Frier   DIABETES-METABOLISM RESEARCH AND REVIEWS